United BioSource (UBC) has acquired Cognitive Drug Research (CDR). The CDR System is used in 1000 trials encompassing approximately 50 different disease areas.
CDR maintains healthy subject, patient, and drug databases of cognitive effects, providing the standard for establishing the clinical relevance of compounds.
The company said that computerized cognitive testing facilitates standardized administration, measurement precision, and the reliability of cognitive endpoints.
Reportedly, the CDR System has demonstrated sensitivity to cognitive enhancements and impairments in a broad range of disorders. Increased sensitivity translates into significant cost savings as fewer study subjects are required to reach statistical significance.
Ethan Leder, CEO of UBC, said: “The premier evidence base, reliability, and global reach of the CDR System coupled with UBC’s validated rater training, assessment, and rater surveillance methods will provide an unprecedented opportunity for improved signal detection in the measurement of cognition and clinically subjective endpoints.”